Intellia Therapeutics (NTLA) Non-Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Non-Current Assets data on file, last reported at $292.3 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $292.3 million, down 32.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 28.13% YoY), and the FY2025 annual result was $314.4 million, down 42.95% from the prior year.
• Non-Current Assets eased to $292.3 million in Q1 2026 per NTLA's latest filing, from $314.4 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $551.2 million in Q4 2024 and troughed at $215.0 million in Q2 2022.
• A 5-year average of $363.1 million and a median of $349.9 million in 2023 frame the typical range for Non-Current Assets.
• On a YoY basis, Non-Current Assets climbed as much as 182.73% in 2022 and fell as far as 56.65% in 2022.
• A 5-year view of Non-Current Assets shows it stood at $303.3 million in 2022, then declined by 0.22% to $302.6 million in 2023, then jumped by 82.11% to $551.2 million in 2024, then slumped by 42.95% to $314.4 million in 2025, then dropped by 7.02% to $292.3 million in 2026.
• Business Quant data shows NTLA's Non-Current Assets at $292.3 million in Q1 2026, $314.4 million in Q4 2025, and $343.3 million in Q3 2025.